Quanterix Corporation (NASDAQ: QTRX) announced the appointment of Jason Faessler as chief financial officer, effective June 22, according to a company statement.

Faessler joins the biomarker detection company from Bruker Corporation, where he served as senior vice president leading global financial planning and analysis and the Americas finance organization. His responsibilities included strategic planning, operational finance, and capital decision-making.

Prior to Bruker, Faessler held senior finance leadership positions at PAREXEL, where he led the company's early- and late-phase clinical divisions. He also held senior financial management roles at EMC, now Dell, and Harvard Business Publishing.

"His extensive track record within life science organizations makes him the ideal leader to support our ambitious growth objectives," said Everett Cunningham, chief executive officer of Quanterix.

Quanterix develops ultra-sensitive biomarker detection technology and acquired Akoya Biosciences in 2025, adding multiplexed tissue imaging capabilities to its portfolio. The combined company has approximately 1,450 installed instruments.